<DOC>
	<DOCNO>NCT00424515</DOCNO>
	<brief_summary>The purpose study evaluate effective imatinib ( Gleevec ) treat acral/lentiginous mucosal melanoma spread part body patient 's disease carry c-kit mutation . Imatinib protein-kinase inhibitor . It believe imatinib may effective blocking signal certain cancer cell allow malignant cell multiply spread .</brief_summary>
	<brief_title>Imatinib Patients With Mucosal Acral/Lentiginous Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine response rate patient metastatic mucosal , acral/lentiginous , chronically sun damage melanoma treatment imatinib . - To determine time progression . Secondary - To correlate c-kit mutational status response therapy . - To evaluate use FDG-PET scanning determine early biologic response therapy . - Tolerability imatinib . - To assess amplification c-kit status quantitative PCR and/or FISH relate molecular pathway target . - To correlate c-kit amplification status response therapy .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Melanomas arise chronically sun damage skin pathologic evidence solar elastosis History primary mucosal acral/lentiginous melanoma Histologically document stage IV metastatic melanoma ECOG performance status 0,1 , 2 Estimated life expectancy 6 month great Age 18 year old Creatinine &lt; 1.5 x ULN ANC &gt; 1500 ul Platelets &gt; 100,000 ul Total bilirubin , AST , ALT &lt; 2 x ULN Amylase lipase &lt; 1.5 x ULN Ckit mutation document either primary metastatic tumor site &gt; 4 week prior chemotherapy investigational drug At least one measurable site disease define least 1 cm great dimension Severe and/or uncontrolled medical disease Pregnant nursing mother Any significant medical , surgical , psychiatric condition interfere compliance Patient &lt; 5 year free another primary malignancy except : basal cell skin cancer cervical carcinoma situ Concurrent treatment Warfarin Prior treatment ckit inhibitor Patient Grade III/IV cardiac problem define NYHA criterion No H2 blockers proton pump inhibitor Known brain metastasis Known chronic liver disease Known diagnosis HIV infection Previous radiotherapy &gt; 25 % bone marrow Major surgery within 2 week prior study entry Patient receive investigational agent within 28 day first study drug dose Chemotherapy within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Imatinib</keyword>
	<keyword>Gleevec</keyword>
</DOC>